Related Experiment Video
Updated: Jul 1, 2026
06:32
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
[Molecular diagnostic testing in gliomas]
1Institut für Neuropathologie, Universitätsklinikum Münster, Domagkstrasse 19, 48129, Münster, Deutschland. hasselblatt@uni-muenster.de
Der Pathologe
|September 10, 2008
Summary
Molecular markers like 1p/19q loss, MGMT promoter methylation, and tyrosine kinase receptor expression are crucial for diagnosing and predicting outcomes in glial tumors. Their use is vital for personalized treatment strategies beyond clinical trials.
Area of Science:
- Neuro-oncology
- Molecular diagnostics
- Cancer biomarkers
Context:
- Glial tumors are the most common central nervous system neoplasms.
- Current guidelines do not mandate routine molecular marker use in treatment decisions.
- Identifying prognostic markers is crucial for patient stratification and novel therapy selection.
Purpose:
- To review methods and rationale for utilizing specific molecular markers in glioma management.
- To highlight the diagnostic, prognostic, and predictive roles of 1p/19q loss, MGMT promoter methylation, and tyrosine kinase receptor expression.
- To emphasize the growing importance of these markers in clinical practice.
Summary:
- This review focuses on 1p/19q loss, MGMT promoter methylation, and tyrosine kinase receptor expression.
- These markers aid in the diagnosis, prognosis, and prediction of treatment response in gliomas.
- The review discusses the methods and scientific basis for their application.
Impact:
- Facilitates more precise glioma classification and patient stratification.
- Supports the development of targeted therapies for specific glioma subgroups.
- Enhances personalized medicine approaches in neuro-oncology, improving patient outcomes.
